NattoPharma: 1st Quarter 2016 earnings release

Please find attached the 1stQuarter 2016 Earnings Release.
Highlights for the quarter,

  · Record quarter revenue at NOK 12,5 million, 84% growth compared to Q1’15
  · Gross Margin at 50,4%, up from 28% same quarter last year
  · EBITDA of NOK -1,7 million, improved from negative NOK -3,7 million same
quarter last year
  · Cash and Cash Equivalents at the end of the period is NOK 26,7 million, up
from NOK 24,7 million at last quarter end (Q4’15)
  · Continued focus on the restructuring of the company to position it for
expected growth, as well as focus on key performance indicators to deliver
improved financial results

A presentation will be held via webcast by CEO Daniel H. Rosenbaum and CFO
Kjetil Ramsøy at 10 am CET, Friday 20th May, followed by a Q&A session directly
thereafter.

Please follow the below link to join the webcast;

http://webtv.hegnar.no/presentation.php?webcastId=33172211

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

Mobil: +47 906 12 943

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D.
NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK
-7, the best documented, commercially available Vitamin K2 as MK-7 with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements. With a global presence, the company established its North American
subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit www.nattopharma.com or www.Menaq7.com